June 17, 2016

 

U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC  20549

 

Re:

Selecta Biosciences Inc.

 

Registration Statement on Form S-1 (File No. 333-211555)

 

Ladies and Gentlemen:

 

As representatives of the several underwriters of Selecta Biosciences Inc’s proposed initial public offering, we hereby join in the request of the registrant that the effectiveness of the above-referenced Registration Statement, as amended, be accelerated to 4:00 p.m. Eastern Standard Time, on June 21, 2016, or as soon thereafter as practicable.

 

In connection with the above-captioned Registration Statement, and pursuant to Rule 460 under the Securities Act of 1933, as amended, please be advised that between June 8, 2016 and the date hereof, approximately 1,300 copies of the Preliminary Prospectus, dated June 8, 2016, were distributed to prospective underwriters, institutional investors and prospective dealers.

 

We have been informed by the participating underwriters that they have complied, and will continue to comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

 

[signature page follows]

 



 

Very truly yours,

 

 

 

 

 

UBS Securities LLC

 

Stifel, Nicolaus & Company, Incorporated

 

As Representatives of the several Underwriters

 

 

 

 

 

By: UBS Securities LLC

 

 

 

By:

/s/ John Hagens

 

 

Name: John Hagens

 

 

Title: Executive Director

 

 

 

By:

/s/ Evan Demcoe

 

 

Name: Evan Demcoe

 

 

Title: Associate Director

 

 

 

 

 

By: Stifel, Nicolaus & Company, Incorporated

 

 

 

By:

/s/ Keith Lister

 

 

Name: Keith Lister

 

 

Title: Managing Director

 

 

[Signature Page to Selecta Biosciences Inc Acceleration Request]